GSK2256294A is primarily investigated for its potential therapeutic applications in treating conditions related to the soluble epoxide hydrolase (sEH) enzyme. By inhibiting sEH, it helps in maintaining the levels of epoxyeicosatrienoic acids (EETs), which are known to have anti-inflammatory, vasodilatory, and organ-protective effects. This makes it a promising candidate for managing pulmonary arterial hypertension, as it can improve vascular function and reduce inflammation in the lungs. Additionally, it is being studied for its role in mitigating chronic obstructive pulmonary disease (COPD) by reducing oxidative stress and inflammation in the airways. There is also emerging research exploring its potential in addressing cardiovascular diseases, diabetes, and kidney disorders, where sEH inhibition could offer protective benefits.